Phase II trial of tamibarotene in combination with chemotherapy or arsenic trioxide as first-line therapy in patients with acute promyelocytic leukaemia.
Phase of Trial: Phase II
Latest Information Update: 26 Jan 2010
At a glance
- Drugs Antineoplastics; Arsenic trioxide; Tamibarotene
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- Sponsors CytRx Corporation
- 26 Jan 2010 New trial record.